Literature DB >> 21606896

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

JoAnn T Tschanz1, Chris D Corcoran, Sarah Schwartz, Katherine Treiber, Robert C Green, Maria C Norton, Michelle M Mielke, Kathleen Piercy, Martin Steinberg, Peter V Rabins, Jeanne-Marie Leoutsakos, Kathleen A Welsh-Bohmer, John C S Breitner, Constantine G Lyketsos.   

Abstract

OBJECTIVES: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains.
DESIGN: Longitudinal, prospective cohort study.
SETTING: Cache County (Utah). PARTICIPANTS: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. MEASUREMENTS: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI).
RESULTS: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were -1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30% to 58% progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r = -0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR χ = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] χ = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E ε 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain.
CONCLUSIONS: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606896      PMCID: PMC3101372          DOI: 10.1097/JGP.0b013e3181faec23

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  42 in total

1.  Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm.

Authors:  H Agüero-Torres; L Fratiglioni; Z Guo; M Viitanen; B Winblad
Journal:  J Am Geriatr Soc       Date:  1998-04       Impact factor: 5.562

Review 2.  Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease.

Authors:  R C Mohs; J Schmeidler; M Aryan
Journal:  Stat Med       Date:  2000 Jun 15-30       Impact factor: 2.373

3.  Predictors of cognitive decline in the early stage of probable Alzheimer's disease.

Authors:  C Marra; M C Silveri; G Gainotti
Journal:  Dement Geriatr Cogn Disord       Date:  2000 Jul-Aug       Impact factor: 2.959

4.  Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales.

Authors:  Sigurd Johnsen; Steve Hughes; Roger Bullock; Ian Hindmarch
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

5.  Vascular factors predict rate of progression in Alzheimer disease.

Authors:  M M Mielke; P B Rosenberg; J Tschanz; L Cook; C Corcoran; K M Hayden; M Norton; P V Rabins; R C Green; K A Welsh-Bohmer; J C S Breitner; R Munger; C G Lyketsos
Journal:  Neurology       Date:  2007-11-06       Impact factor: 9.910

6.  Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries.

Authors:  Ilene H Zuckerman; Priscilla T Ryder; Linda Simoni-Wastila; Thomas Shaffer; Masayo Sato; Lirong Zhao; Bruce Stuart
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2008-09       Impact factor: 4.077

7.  Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples.

Authors:  D Tsuang; W Kukull; L Sheppard; R L Barnhart; E Peskind; S D Edland; G Schellenberg; M Raskind; E B Larson
Journal:  J Am Geriatr Soc       Date:  1996-06       Impact factor: 5.562

8.  Education, cognitive function, and severity of neuropathology in Alzheimer disease.

Authors:  T D Koepsell; B F Kurland; O Harel; E A Johnson; X-H Zhou; W A Kukull
Journal:  Neurology       Date:  2007-12-26       Impact factor: 9.910

9.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

10.  APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.

Authors:  S Cosentino; N Scarmeas; E Helzner; M M Glymour; J Brandt; M Albert; D Blacker; Y Stern
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

View more
  101 in total

1.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

3.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

4.  Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.

Authors:  Michelle M Mielke; Jeannie-Marie Leoutsakos; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; JoAnn T Tschanz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 5.  Amyloid positron emission tomography and cognitive reserve.

Authors:  Matteo Bauckneht; Agnese Picco; Flavio Nobili; Silvia Morbelli
Journal:  World J Radiol       Date:  2015-12-28

6.  Caregiver personality predicts rate of cognitive decline in a community sample of persons with Alzheimer's disease. The Cache County Dementia Progression Study.

Authors:  Maria C Norton; Christine Clark; Elizabeth B Fauth; Kathleen W Piercy; Roxane Pfister; Robert C Green; Christopher D Corcoran; Peter V Rabins; Constantine G Lyketsos; Joann T Tschanz
Journal:  Int Psychogeriatr       Date:  2013-07-05       Impact factor: 3.878

7.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

Authors:  Stephanie Behrens; Gail B Rattinger; Sarah Schwartz; Joshua Matyi; Chelsea Sanders; M Scott DeBerard; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2018-03-21       Impact factor: 3.878

Review 8.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

9.  Predictors of dementia caregiver depressive symptoms in a population: the Cache County dementia progression study.

Authors:  Kathleen W Piercy; Elizabeth B Fauth; Maria C Norton; Roxane Pfister; Chris D Corcoran; Peter V Rabins; Constantine Lyketsos; JoAnn T Tschanz
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2012-12-14       Impact factor: 4.077

10.  Dementia caregivers' coping strategies and their relationship to health and well-being: the Cache County Study.

Authors:  Christine M Snyder; Elizabeth Fauth; Joseph Wanzek; Kathleen W Piercy; Maria C Norton; Chris Corcoran; Peter V Rabins; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Aging Ment Health       Date:  2014-08-05       Impact factor: 3.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.